10-Q: ALX Oncology Narrows Focus Amidst Clinical Setbacks

ALX Oncology reported reduced Q2 2025 net losses but announced significant pipeline shifts, including abandoning a U.S. gastric cancer approval path and discontinuing an HNSCC program, while facing Nasdaq delisting risk.

Summary

• Net loss significantly decreased to $25.9 million for the three months ended June 30, 2025, a 34% reduction from $39.4 million in the same period of 2024.
• Research and development (R&D) expenses decreased by 48% to $18.0 million in Q2 2025, primarily due to completed clinical trial material manufacturing and a workforce reduction.
• General and administrative (G&A) expenses decreased by 21% to $5.5 million in Q2 2025.
• An impairment charge of $3.2 million was recognized in Q2 2025 related to the decision to sublease a leased property in Palo Alto.
• Cash, cash equivalents, and investments totaled $83.5 million as of June 30, 2025, projected to fund operations into the first quarter of 2027.
• The company will not pursue a U.S. registrational path for evorpacept in gastric cancer (ASPEN-06) due to FDA guidance and the availability of ENHERTU, and will consider development partnerships instead.
• Evorpacept development program was streamlined, pausing the ASPEN-CRC study in colorectal cancer to focus resources on the ASPEN-Breast trial.
• Topline data from ASPEN-03 and ASPEN-04 clinical trials in head and neck squamous cell carcinoma (HNSCC) did not meet primary endpoints, leading to the discontinuation of evorpacept in this indication.
• ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), received IND clearance from the FDA and is anticipated to enter Phase 1 trials in August 2025.
• The company received a Nasdaq notice on April 23, 2025, for non-compliance with the minimum bid price requirement ($1.00), with a compliance period until October 20, 2025.

Sentiment

Score: 4

Explanation: While the company reduced its net loss and has a cash runway into Q1 2027, the significant setbacks in key clinical programs (HNSCC discontinuation, gastric cancer approval path abandonment, CRC study pause) and the Nasdaq delisting risk are major concerns. The positive biomarker data in gastric cancer and the new ADC program offer some upside, but the overall strategic retrenchment and market challenges weigh heavily on the sentiment.

Positives

• Net loss significantly reduced by 34% in Q2 2025 compared to Q2 2024, and by 24% for the six months ended June 30, 2025, compared to the same period in 2024.
• Research and development expenses decreased substantially by 48% in Q2 2025 and 37% for the six months, reflecting pipeline prioritization and cost management.
• Cash, cash equivalents, and investments of $83.5 million are projected to fund operations into Q1 2027, providing a runway of over 18 months.
• Positive exploratory analysis from the ASPEN-06 trial identified CD47 overexpression as a key predictive biomarker for evorpacept response in HER2-positive gastric cancer, showing a 65% ORR in CD47-high patients versus 26% with TRP alone.
• ALX2004, a novel EGFR-targeted ADC, received IND clearance from the FDA and is anticipated to enter Phase 1 trials in August 2025, diversifying the pipeline.
• Strong clinical data from MD Anderson Cancer Center's investigator-sponsored trial (IST) of evorpacept in relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) showed a 94% overall response rate (ORR) and 83% complete response rate in indolent R/R B-NHL patients.
• Appointment of Daniel Curran, M.D. to the Board of Directors adds medical expertise.

Negatives

• Decision not to pursue a U.S. registrational path for evorpacept in gastric cancer (ASPEN-06) due to FDA guidance and ENHERTU availability, limiting a potential key indication.
• Discontinuation of evorpacept development in HNSCC (ASPEN-03 and ASPEN-04 trials) after failing to meet primary endpoints.
• Pausing of the ASPEN-CRC study in colorectal cancer, further narrowing the evorpacept development pipeline.
• Accumulated deficit increased to $677.8 million as of June 30, 2025, indicating continued historical losses.
• Received a Nasdaq notice for non-compliance with the minimum bid price requirement ($1.00), with the stock closing below $1.00 since March 10, 2025, posing a delisting risk.
• Incurred a $3.2 million impairment charge related to subleasing a leased property in Palo Alto.
• Cash, cash equivalents, and investments decreased from $129.2 million at December 31, 2024, to $83.5 million at June 30, 2025.
• Net cash used in financing activities shifted from provided ($30.2 million) in H1 2024 to used ($(0.2) million) in H1 2025, indicating less reliance on equity raises in the current period.

Risks

• Incurred significant net losses since inception and expects to continue incurring significant net losses for the foreseeable future.
• Requires substantial additional capital to finance operations, which may not be available on acceptable terms, potentially forcing delays or elimination of research and development programs.
• Has a limited operating history with no products approved for commercial sale and has not generated any revenue from product sales, licenses, or collaborations to date.
• Is substantially dependent on the success of its lead product candidate, evorpacept, which is in clinical development and has not completed a pivotal trial.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of clinical trials may not satisfy regulatory requirements.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with potential for failure to demonstrate adequate safety, efficacy, and potency.
• Product candidates may cause significant adverse events or undesirable side effects, potentially preventing regulatory approval, market acceptance, or leading to negative consequences.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, which could lead to inability to generate product revenue.
• Inability to obtain, maintain, and enforce patent protection and other intellectual property for product candidates and related technology could materially harm the business.
• Highly dependent on key personnel and risks not attracting, motivating, and retaining highly qualified personnel, potentially hindering business strategy implementation.
• Relies on third-party manufacturers for clinical supplies, increasing the risk of insufficient quantities, unacceptable cost, or quality issues.
• Debt levels and compliance with loan agreement terms could restrict business operations and lead to default.
• Macroeconomic conditions and global economic environment (inflation, interest rate changes, trade disputes, economic downturns, bank failures, geopolitical risks, public health crises) could adversely impact the business.
• Risk of common stock delisting from Nasdaq Global Select Market if minimum bid price requirements are not met.
• Stock price volatility, potentially leading to loss of investment.
• Past material weaknesses in internal control over financial reporting, with future risk of inability to maintain effective controls.
• Potential for costly and damaging product liability claims, with insurance possibly not covering all damages.
• Risk of expending limited resources on less profitable or less successful product candidates or indications.
• Challenges in establishing and maintaining collaborations, potentially leading to delays or termination of development.
• Exposure to business, regulatory, political, operational, financial, pricing, and reimbursement risks associated with international operations.
• Disruptions and delays from system failures or security breaches.
• Risk of securities litigation.
• Dependence on subsidiaries' operations and cash flows as a holding company.
• Potential for dilution from future capital raises.
• Delaware law and charter provisions might discourage change in control.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses as it advances evorpacept through multiple clinical trials and pursues regulatory approval, and progresses ALX2004 into Phase 1 trials. Existing capital resources are believed to be sufficient to fund operations into the first quarter of 2027, but additional funding will be required to fully implement the business plan, potentially through equity offerings, debt financings, or strategic alliances. The company will not pursue a U.S. registrational path for evorpacept in gastric cancer but will explore development partnerships for this program. Future growth will require additional personnel and expanded infrastructure.

Management Comments

• We believe that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.
• We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• We expect our expenses will increase substantially in connection with our ongoing activities, as we advance evorpacept through multiple clinical trials in multiple indications; pursue regulatory approval of evorpacept in solid tumors and hematological malignancies; advance ALX2004 through a first-in-human trial; continue preclinical and clinical development efforts; obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates; manufacture supplies for our preclinical studies and clinical trials; and continue to add operational, financial and management information systems to support ongoing operations as a public company.
• Given our disciplined focus and the allocation of our resources, we will not pursue a U.S. registrational path with a Phase 3 trial in gastric cancer and will consider exploring development partnerships to advance this program in gastric cancer.
• We streamlined evorpacept development program to focus our resources on the ASPEN-Breast trial and paused the ASPEN-CRC study announced earlier in March 2025.
• We intend to actively monitor the closing bid price of our common stock and assess potential actions to regain compliance during the 180-calendar day compliance period, including effecting a reverse stock split, if necessary.

Industry Context

The biotechnology industry, particularly in oncology, is highly competitive and capital-intensive, with significant R&D costs and lengthy regulatory approval processes. ALX Oncology's strategic shift to prioritize certain pipeline assets and discontinue others reflects a common industry trend of resource optimization in response to clinical trial outcomes and regulatory feedback. The focus on biomarker-driven patient selection (CD47-high) for evorpacept aligns with precision medicine trends aimed at improving response rates and drug development efficiency. The entry into the ADC space with ALX2004 indicates diversification within the oncology therapeutic area, a growing segment with high interest. The company's financial position and Nasdaq compliance issues highlight the challenges faced by clinical-stage biotechs in maintaining liquidity and market valuation amidst development uncertainties and broader economic pressures.

Comparison to Industry Standards

• The decision to not pursue a U.S. registrational path for evorpacept in gastric cancer due to the availability of ENHERTU (fam-trastuzumab deruxtecan-nxki) indicates that ENHERTU, an approved HER2-targeted ADC, sets a high bar for efficacy and regulatory approval in this space.
• The 65% ORR for evorpacept combined with TRP in confirmed HER2-positive, CD47-high gastric cancer patients (n=43) compares favorably to the 26% ORR with TRP alone in the same subset, and also to the 30% ORR for ramucirumab and paclitaxel (RP) historical control and 26.6% for TRP control in the overall ASPEN-06 ITT population. This suggests a strong signal in a specific biomarker-defined patient group.
• The 94% ORR and 83% complete response rate in indolent R/R B-NHL patients from the MD Anderson IST of evorpacept in combination with R2 are very strong results, especially compared to typical response rates in relapsed/refractory settings for B-NHL.
• The development of ALX2004, an EGFR-targeted ADC, positions the company in a competitive but potentially lucrative area, as there are currently no approved EGFR-targeted ADCs, despite EGFR being a clinically validated target. This contrasts with the success of HER2-targeted ADCs like ENHERTU.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Potential for future involvement in legal proceedings arising in the ordinary course of business.

Related Party Transactions

• Tallac Collaboration Agreement: Recorded $40,000 in R&D costs for Q2 2025 and $0.1 million for H1 2025. Accrued expenses of $40,000 as of June 30, 2025.
• Tallac Services Agreement: Terminated on July 1, 2024.
• ScalmiBio Milestone Payments: No milestone payments made in Q2 2025 or H1 2025. In H1 2024, a $1.0 million milestone payment was made for selecting a development candidate, with portions paid to former CEO/CSO and another employee.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity offerings. Risk of delisting from Nasdaq could negatively impact liquidity and stock price. Volatility in stock price is expected.
• Employees: Reduction in workforce (RIF) by approximately 30% in Q1 2025 due to pipeline prioritization, potentially impacting morale and institutional knowledge. Competition for skilled personnel remains intense.
• Patients: Discontinuation of evorpacept in HNSCC and abandonment of U.S. registrational path in gastric cancer means these patient populations will not benefit from evorpacept from ALX Oncology. However, the focus on ASPEN-Breast and the new ALX2004 program could benefit other patient groups.
• Creditors: Compliance with all financial reporting covenants under the Loan Agreement as of June 30, 2025. The company has $25.0 million available from the term loan at the lenders' discretion.
• Partners/Collaborators: Strategic shifts may impact existing or future collaborations, but the company is exploring development partnerships for gastric cancer.

Next Steps

• Present full data set from ASPEN-06 exploratory analysis (CD47 biomarker) at an upcoming medical conference in Q4 2025.
• ALX2004 (EGFR-targeted ADC) anticipated to enter Phase 1 trials in August 2025.
• Sanofi to begin dose optimization portion of the UMBRELLA study (evorpacept with isatuximab-irfc and dexamethasone in multiple myeloma).
• Actively monitor Nasdaq bid price and assess potential actions to regain compliance, including a reverse stock split if necessary.
• Continue to invest in research and development activities related to existing product candidates and advance ALX2004.
• Seek additional funding through equity offerings, debt financings, collaborations, strategic alliances, or marketing/distribution/licensing arrangements.
• Evaluate the impact of new accounting guidance (ASU 2023-09 and ASU 2024-03) on financial statements.

Key Dates

Recommendation

The company faces significant headwinds, including the abandonment of a U.S. registrational path for its lead candidate evorpacept in gastric cancer and the discontinuation of its HNSCC program, which represent major setbacks for its pipeline. While cost reductions have improved the net loss, the underlying strategic retrenchment and the Nasdaq delisting risk due to sustained low share price indicate fundamental challenges. The cash runway into Q1 2027 is positive, but the need for substantial additional capital, coupled with a volatile market and a history of significant losses, suggests high investment risk. Despite some promising biomarker data and a new ADC program, the overall outlook is concerning, warranting a 'sell' recommendation for investors to mitigate further potential losses given the significant clinical and market uncertainties.

Keywords

ALX Oncology, ALXO, Biotechnology, Oncology, Cancer Therapy, Evorpacept, CD47 Blocker, ALX2004, EGFR-targeted ADC, Clinical Trials, Drug Development, Immuno-oncology, HER2-positive Gastric Cancer, Breast Cancer, Non-Hodgkin Lymphoma, Multiple Myeloma, Nasdaq Compliance, SEC Filing, 10-Q, Biomarker, Pipeline Prioritization, Financial Results